Consultation on draft guidance recommending treatments for types of arthritis that affecting spine NICE has today published draft guidance on adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer), infliximab (Remicade, Merck Sharp & Dohme; Inflectra, Hospira; Remsima, Celltrion), certolizumab pegol (Cimzia, UCB Pharma) and golimumab (Simponi, Merck Sharp & Dohme) – known as TNF-alpha inhibitors – for…
